Skip to main content Accessibility help

The role of dopamine D3 receptors in the mechanism of action of cariprazine

  • Francesca Calabrese (a1), Frank I. Tarazi (a2), Giorgio Racagni (a1) (a3) and Marco A. Riva (a1)


Cariprazine is a new atypical antipsychotic drug (APD) with a unique pharmacodynamic profile, different from both typical and atypical APDs. Specifically, cariprazine acts as a partial agonist at the dopamine (DA) D2 and D3 receptors and serotonin 5-HT1A receptors, and as an antagonist at the 5-HT2B receptors. Moreover, it shows moderate affinities for adrenergic, histaminergic, and cholinergic receptors that are involved in mediating the side effects characteristic of typical APDs. In this review, we discuss the contribution of DA D3 receptors (D3Rs) in the etiology and pathophysiology of schizophrenia and the potential benefits that may be associated with a more selective targeting of D3R by APDs, as compared to other dopaminergic and non-dopaminergic receptor subtypes. Cariprazine, by acting on D3Rs, ameliorates anhedonia and cognitive deficits in animal models based on environmental or pharmacological manipulation. The reviewed results support the potential benefits of cariprazine in treating negative symptoms and cognitive deficits of schizophrenia, and therefore representing a promising approach in addressing the unmet clinical needs for the improved treatment of this serious neuropsychiatric disorder.


Corresponding author

*Address correspondence to: Marco A. Riva, Professor, Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Balzaretti 9, 20133 Milan, Italy. (Email:


Hide All
1. Biesdorf, C, Wang, AL, Topic, B, et al. Dopamine in the nucleus accumbens core, but not shell, increases during signaled food reward and decreases during delayed extinction. Neurobiol Learn Mem. 2015; 123: 125139.
2. Cools, R, D’Esposito, M. Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol Psychiatry. 2011; 69(12): e113e125.
3. Hamid, AA, Pettibone, JR, Mabrouk, OS, et al. Mesolimbic dopamine signals the value of work. Nat Neurosci. 2016; 19(1): 117126.
4. Kegeles, LS, Abi-Dargham, A, Frankle, WG, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry. 2010; 67(3): 231239.
5. Gingrich, JA, Caron, MG. Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci. 1993; 16: 299321.
6. Sibley, DR, Monsma, FJ Jr. Molecular biology of dopamine receptors. Trends Pharmacol Sci. 1992; 13(2): 6169.
7. Beaulieu, JM, Gainetdinov, RR, Caron, MG. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci. 2007; 28(4): 166172.
8. Leucht, S, Davis, JM. Schizophrenia, primary negative symptoms, and soft outcomes in psychiatry. Lancet. 2017; 389(10074): 10771078.
9. Potkin, SG, Loze, JY, Forray, C, et al. Multidimensional assessment of functional outcomes in schizophrenia: results from QUALIFY, a head-to-head trial of aripiprazole once-monthly and paliperidone palmitate. Int J Neuropsychopharmacol. 2017; 20(1): 4049.
10. Nemeth, G, Laszlovszky, I, Czobor, P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017; 389(10074): 11031113.
11. Tsapakis, EM, Dimopoulou, T, Tarazi, FI. Clinical management of negative symptoms of schizophrenia: an update. Pharmacol Ther. 2015; 153: 135147.
12. Sokoloff, P, Giros, B, Martres, MP, Bouthenet, ML, Schwartz, JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 1990; 347(6289): 146151.
13. Gurevich, EV, Joyce, JN. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology. 1999; 20(1): 6080.
14. Sokoloff, P, Le Foll, B. The dopamine D3 receptor, a quarter century later. Eur J Neurosci. 2017; 45(1): 219.
15. Sokoloff, P, Diaz, J, Le Foll, B, et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets. 2006; 5(1): 2543.
16. Stahl, SM. Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors. CNS Spectr. 2017; 22(4): 305311.
17. Grace, AA. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. Nat Rev Neurosci. 2016; 17(8): 524532.
18. Kapur, S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003; 160(1): 1323.
19. Maggio, R, Scarselli, M, Capannolo, M, Millan, MJ. Novel dimensions of D3 receptor function: focus on heterodimerisation, transactivation and allosteric modulation. Eur Neuropsychopharmacol. 2015; 25(9): 14701479.
20. Scarselli, M, Novi, F, Schallmach, E, et al. D2/D3 dopamine receptor heterodimers exhibit unique functional properties. J Biol Chem. 2001; 276(32): 3030830314.
21. Fiorentini, C, Busi, C, Spano, P, Missale, C. Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson’s disease. Parkinsonism Relat Disord. 2008; 14(Suppl 2): S159S164.
22. Marcellino, D, Ferre, S, Casado, V, et al. Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J Biol Chem. 2008; 283(38): 2601626025.
23. Torvinen, M, Marcellino, D, Canals, M, et al. Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A/D3 heteromeric complexes. Mol Pharmacol. 2005; 67(2): 400407.
24. Collo, G, Bono, F, Cavalleri, L, et al. Nicotine-induced structural plasticity in mesencephalic dopaminergic neurons is mediated by dopamine D3 receptors and Akt-mTORC1 signaling. Mol Pharmacol. 2013; 83(6): 11761189.
25. Cussac, D, Newman-Tancredi, A, Pasteau, V, Millan, MJ. Human dopamine D(3) receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism. Mol Pharmacol. 1999; 56(5): 10251030.
26. Collo, G, Zanetti, S, Missale, C, Spano, P. Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation. Eur J Neurosci. 2008; 28(7): 12311240.
27. Schwartz, JC, Diaz, J, Pilon, C, Sokoloff, P. Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res Brain Res Rev. 2000; 31(2-3): 277287.
28. Gyertyan, I, Saghy, K. Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U 99194A and SB 277011. Behav Pharmacol. 2004; 15(4): 253262.
29. Nakajima, S, Gerretsen, P, Takeuchi, H, et al. The potential role of dopamine D(3) receptor neurotransmission in cognition. Eur Neuropsychopharmacol. 2013; 23(8): 799813.
30. Barth, V, Need, AB, Tzavara, ET, et al. In vivo occupancy of dopamine D3 receptors by antagonists produces neurochemical and behavioral effects of potential relevance to attention-deficit-hyperactivity disorder. J Pharmacol Exp Ther. 2013; 344(2): 501510.
31. Laszy, J, Laszlovszky, I, Gyertyan, I. Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology (Berl). 2005; 179(3): 567575.
32. Millan, MJ, Di Cara, B, Dekeyne, A, et al. Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J Neurochem. 2007; 100(4): 10471061.
33. Watson, DJ, Loiseau, F, Ingallinesi, M, Millan, MJ, Marsden, CA, Fone, KC. Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex. Neuropsychopharmacology. 2012; 37(3): 770786.
34. Lumme, V, Aalto, S, Ilonen, T, Nagren, K, Hietala, J. Dopamine D2/D3 receptor binding in the anterior cingulate cortex and executive functioning. Psychiatry Res. 2007; 156(1): 6974.
35. Simpson, EH, Winiger, V, Biezonski, DK, Haq, I, Kandel, ER, Kellendonk, C. Selective overexpression of dopamine D3 receptors in the striatum disrupts motivation but not cognition. Biol Psychiatry. 2014; 76(10): 823831.
36. Gross, G, Wicke, K, Drescher, KU. Dopamine D(3) receptor antagonism--still a therapeutic option for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol. 2013; 386(2): 155166.
37. Joyce, JN, Millan, MJ. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today. 2005; 10(13): 917925.
38. Van Kampen, JM, Eckman, CB. Dopamine D3 receptor agonist delivery to a model of Parkinson’s disease restores the nigrostriatal pathway and improves locomotor behavior. J Neurosci. 2006; 26(27): 72727280.
39. Mailman, RB, Murthy, V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010; 16(5): 488501.
40. Pich, EM, Collo, G. Pharmacological targeting of dopamine D3 receptors: possible clinical applications of selective drugs. Eur Neuropsychopharmacol. 2015; 25(9): 14371447.
41. Frankel, JS, Schwartz, TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol. 2017; 7(1): 2941.
42. Miyamoto, S, Duncan, GE, Marx, CE, Lieberman, JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005; 10(1): 79104.
43. Kiss, B, Horvath, A, Nemethy, Z, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010; 333(1): 328340.
44. Veselinovic, T, Paulzen, M, Grunder, G. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression. Expert Rev Neurother. 2013; 13(11): 11411159.
45. Goff, DC. Brexpiprazole: a new antipsychotic following in the footsteps of aripiprazole. Am J Psychiatry. 2015; 172(9): 820821.
46. Stahl, SM. Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes. CNS Spectr. 2017; 22(5): 375384.
47. Nakamura, T, Kubota, T, Iwakaji, A, Imada, M, Kapas, M, Morio, Y. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des Devel Ther. 2016; 10: 327338.
48. Garnock-Jones, KP. Cariprazine: a review in schizophrenia. CNS Drugs. 2017; 31(6): 513525.
49. De Berardis, D, Orsolini, L, Iasevoli, F, et al. The novel antipsychotic cariprazine (RGH-188): State-of-the-art in the treatment of psychiatric disorders. Curr Pharm Des. 2016; 22(33): 51445162.
50. Calabrese, JR, Keck, PE Jr., Starace, A, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015; 76(3): 284292.
51. Durgam, S, Cutler, AJ, Lu, K, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015; 76(12):e1574e1582.
52. Durgam, S, Greenberg, WM, Li, D, et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. Psychopharmacology (Berl). 2017; 234(2): 199209.
53. Durgam, S, Starace, A, Li, D, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014; 152(2-3): 450457.
54. Kane, JM, Zukin, S, Wang, Y, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: Results from an international, phase III clinical trial. J Clin Psychopharmacol. 2015; 35(4): 367373.
55. Cutler, AJ, Durgam, S, Wang, Y, et al. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectr. 2017: 112.
56. Ketter, TA, Sachs, GS, Durgam, S, et al. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study. J Affect Disord. 2018; 225: 350356.
57. Earley, W, Durgam, S, Lu, K, Laszlovszky, I, Debelle, M, Kane, JM. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2017; 32(6): 319328.
58. Nasrallah, HA, Earley, W, Cutler, AJ, et al. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. BMC Psychiatry. 2017; 17(1): 305.
59. Buchanan, RW, Breier, A, Kirkpatrick, B, Ball, P, Carpenter, WT, Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry. 1998; 155(6): 751760.
60. Nemeth, B, Molnar, A, Akehurst, R, et al. Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. J Comp Eff Res. 2017; 6(8): 639648.
61. Choi, YK, Adham, N, Kiss, B, Gyertyan, I, Tarazi, FI. Long-term effects of cariprazine exposure on dopamine receptor subtypes. CNS Spectr. 2014; 19(3): 268277.
62. Tarazi, FI, Florijn, WJ, Creese, I. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment. Neuroscience. 1997; 78(4): 985996.
63. Tarazi, FI, Yeghiayan, SK, Baldessarini, RJ, Kula, NS, Neumeyer, JL. Long-term effects of S(+)N-n-propylnorapomorphine compared with typical and atypical antipsychotics: differential increases of cerebrocortical D2-like and striatolimbic D4-like dopamine receptors. Neuropsychopharmacology. 1997; 17(3): 186196.
64. Tarazi, FI, Zhang, K, Baldessarini, RJ. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther. 2001; 297(2): 711717.
65. Tarazi, FI, Moran-Gates, T, Wong, EH, Henry, B, Shahid, M. Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Psychopharmacology (Berl). 2008; 198(1): 103111.
66. Gyertyan, I, Kiss, B, Saghy, K, et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011; 59(6): 925935.
67. Zhang, K, Weiss, NT, Tarazi, FI, Kula, NS, Baldessarini, RJ. Effects of alkylating agents on dopamine D(3) receptors in rat brain: selective protection by dopamine. Brain Res. 1999; 847(1): 3237.
68. Harvey, PD, Wingo, AP, Burdick, KE, Baldessarini, RJ. Cognition and disability in bipolar disorder: lessons from schizophrenia research. Bipolar Disord. 2010; 12(4): 364375.
69. Baldessarini, RJ, Tarazi, FI. Pharmacotherapy of psychosis and mania. In: Brunton, LL, Lazo, JS, Parker, KL, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill; 2005:461500.
70. Citrome, L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Ther. 2013; 30(2): 114126.
71. Citrome, L. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy. Adv Ther. 2013; 30(2): 102113.
72. Choi, YK, Adham, N, Kiss, B, Gyertyan, I, Tarazi, FI. Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine. CNS Spectr. 2017: 111.
73. Tarazi, FI, Zhang, K, Baldessarini, RJ. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berl). 2002; 161(3): 263270.
74. Tarazi, FI, Baldessarini, RJ, Kula, NS, Zhang, K. Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J Pharmacol Exp Ther. 2003; 306(3): 11451151.
75. Tarazi, FI, Choi, YK, Gardner, M, Wong, EH, Henry, B, Shahid, M. Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse. 2009; 63(5): 413420.
76. Tarazi, FI, Florijn, WJ, Creese, I. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology (Berl). 1996; 128(4): 371379.
77. Tarsy, D, Baldessarini, RJ, Tarazi, FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 2002; 16(1): 2345.
78. Tsai, G, Coyle, JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol. 2002; 42: 165179.
79. Zimnisky, R, Chang, G, Gyertyan, I, Kiss, B, Adham, N, Schmauss, C. Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl). 2013; 226(1): 91100.
80. Barnes, SA, Young, JW, Markou, A, Adham, N, Gyertyan, I, Kiss, B. The effects of cariprazine and aripiprazole on PCP-induced deficits on attention assessed in the 5-choice serial reaction time task. Psychopharmacology (Berl). 2018; 235(5): 14031414.
81. Neill, JC, Grayson, B, Kiss, B, Gyertyan, I, Ferguson, P, Adham, N. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. Eur Neuropsychopharmacol. 2016; 26(1): 314.
82. Reinwald, JR, Becker, R, Mallien, AS, et al. Neural mechanisms of early-life social stress as a developmental risk factor for severe psychiatric disorders. Biol Psychiatry. 2017.
83. Watson, DJG, King, MV, Gyertyan, I, Kiss, B, Adham, N, Fone, KCF. The dopamine D(3)-preferring D(2)/D(3) dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia. Eur Neuropsychopharmacol. 2016; 26(2): 208224.
84. Duric, V, Banasr, M, Franklin, T, et al. Cariprazine exhibits anxiolytic and dopamine D3 receptor-dependent antidepressant effects in the chronic stress model. Int J Neuropsychopharmacol. 2017; 20(10): 788796.
85. Papp, M, Gruca, P, Lason-Tyburkiewicz, M, Adham, N, Kiss, B, Gyertyan, I. Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. Behav Pharmacol. 2014; 25(5-6): 567574.
86. Chourbaji, S, Brandwein, C, Vogt, MA, et al. Dopamine receptor 3 (D3) knockout mice show regular emotional behaviour. Pharmacol Res. 2008; 58(5-6): 302307.
87. Leggio, GM, Micale, V, Drago, F. Increased sensitivity to antidepressants of D3 dopamine receptor-deficient mice in the forced swim test (FST). Eur Neuropsychopharmacol. 2008; 18(4): 271277.
88. Meltzer, HY, Huang, M, He, W, Kiss, B, Farkas, B, Adham, N. Cariprazine enhances monoaminergic activity in the hippocampus and ventral striatum of rats: A possible basis for its antipsychotic effect. Biol Psychiatry 2018; 83(9, supplement): S228.


The role of dopamine D3 receptors in the mechanism of action of cariprazine

  • Francesca Calabrese (a1), Frank I. Tarazi (a2), Giorgio Racagni (a1) (a3) and Marco A. Riva (a1)


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed